# Physics, Free Energy, & Drug Discovery: Inside Schrödinger's Computational Platform

Page: https://stenobird.com/podcast/data-in-biotech-6628050/physics-free-energy-drug-discovery-inside-schr-dinger-s-computational-platform
Text version: https://stenobird.com/podcast/data-in-biotech-6628050/physics-free-energy-drug-discovery-inside-schr-dinger-s-computational-platform.md
Podcast: [Data in Biotech](https://stenobird.com/podcast/data-in-biotech-6628050)
Published: 2026-04-01T17:00:34+00:00
Episode link: https://www.corrdyn.com/
Audio file: https://downloads.pod.co/5fac40cd-043b-485f-838d-c63fa01ae1b2/a855a522-a5ec-46a8-ad2e-7287bff4d420.mp3
Processing state: not_requested
JSON: https://stenobird.com/v1/public/podcasts/data-in-biotech-6628050/episodes/physics-free-energy-drug-discovery-inside-schr-dinger-s-computational-platform
Duration seconds: 3451

## Resource

In this episode of Data in Biotech, Ross Katz sits down with Robert Abel, Chief Scientific Officer of the Platform at Schrödinger, to explore how physics-based computational modeling is transforming drug discovery. Robert unpacks why machine learning alone isn't enough to navigate the vast complexity of chemical space - an estimated at 10⁶⁰ possible drug-like molecules - and how integrating atomistic simulations with ML creates a more accurate, reliable, and scalable approach to identifying viable drug candidates. From free energy perturbation calculations to generative AI, Robert offers a rare inside look at how Schrödinger's technology platform is accelerating the path from target identification to clinical candidate and where the field is headed next. What you’ll learn in this episode: >> Why chemical space (~10⁶⁰ molecules) makes purely data-driven ML approaches fundamentally insufficient for drug discovery, and how physics-based sampling solves the training data problem >> How free energy perturbation (FEP) calculations enable quantitative prediction of protein-ligand binding affinities at near-experimental accuracy (~1.2 kcal/mol RMSE) >> How Schrödinger's active learning framework combines physics-based simulations and ML to triage billions of candidate molecules before committing to wet lab synthesis >> Why Schrödinger operates across three business lines; software licensing, collaborative programs, and proprietary drug discovery and how each strengthens the underlying technology platform >> Where the next frontiers lie: routine anti-target selectivity profiling, retrosynthetic AI integration, and the expanding role of generative ML in de novo molecular design Meet our guest: Robert Abel is Chief Scientific Officer, Platform at Sch…

## Actions

- request_transcript: `POST https://stenobird.com/v1/public/podcasts/data-in-biotech-6628050/episodes/physics-free-energy-drug-discovery-inside-schr-dinger-s-computational-platform/transcription-requests` — Idempotently request low-priority transcript generation for this episode.
- read_markdown: `GET https://stenobird.com/podcast/data-in-biotech-6628050/physics-free-energy-drug-discovery-inside-schr-dinger-s-computational-platform.md` — Read the agent-friendly Markdown representation of this episode resource.

A page view does not enqueue transcription. Agents should invoke `request_transcript` explicitly when they need this episode processed.

## Transcript

Full transcripts are not published on public pages unless there is a clear rights basis.